Consistent with this, sorafenib treatment led to increased infiltration of Gr1+ neutrophils in hepatoma tissues, an effect that was absent in TRIB3 knockout hepatoma cells or was suppressed by administration of the CXCR1/2 inhibitor Reparixin (Figure 5C,D; Figure S5D, Supporting Information). The gene discussed is TRIB3; the disease is hepatocellular carcinoma.